CD8A and neoplasm: We thus resorted to determine if the anti-tumor activity of combined GARP:TGF-β1/PD-1 blockade could encompass other mechanisms than increasing the effector functions of anti-tumor CD8 T cells already present within tumors, as observed in CT26.